Canaccord Genuity Group Cuts Neuronetics Price Target to $3.00

The firm maintains a buy rating on the stock despite the reduced price target.

Mar. 22, 2026 at 6:20am

Got story updates? Submit your updates here. ›

Neuronetics (NASDAQ:STIM) had its price target trimmed by Canaccord Genuity Group from $7.00 to $3.00 in a report issued on Thursday. The firm currently has a buy rating on the stock. Several other equity research analysts have also recently weighed in on the company, with one issuing a sell rating and one raising the stock to a hold rating.

Why it matters

Neuronetics is a medical technology company that develops and markets non-invasive neuromodulation therapies, including its flagship NeuroStar Advanced Therapy System. The reduced price target from Canaccord Genuity Group suggests some near-term challenges for the company, but the firm's maintained buy rating indicates it still sees long-term potential in Neuronetics' business.

The details

Canaccord Genuity Group cited the company's recent quarterly earnings report, in which Neuronetics reported a loss of $0.10 per share but exceeded analyst expectations. The firm also noted the company's ongoing efforts to advance its clinical research and commercialize its neuromodulation therapies.

  • Canaccord Genuity Group issued the report on Thursday, March 22, 2026.
  • Neuronetics reported its latest quarterly earnings on Tuesday, March 17, 2026.

The players

Canaccord Genuity Group

A global financial services firm that provides investment banking, advisory, equity research, sales and trading services.

Neuronetics

A commercial-stage medical technology company that develops and markets non-invasive neuromodulation therapies, including the NeuroStar Advanced Therapy System.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

The takeaway

The reduced price target from Canaccord Genuity Group suggests some near-term challenges for Neuronetics, but the firm's maintained buy rating indicates it still sees long-term potential in the company's neuromodulation therapies, which could have important implications for the treatment of psychiatric and neurological disorders.